Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16036853 | 0.89 | PIK3R1 (0.48) | KMT2AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL25221709 | 0.83 | HTT (0.49) | KMT2AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2811716 | 0.80 | KMT2A (0.46) | KMT2AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL11827419 | 0.79 | HSD17B10 (0.50) | KMT2ASMN1; SMN2MAPK1MEN1TDP1 | |
| SCHEMBL2815267 | 0.79 | MAPK1 (0.51) | KMT2AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL11864650 | 0.79 | MAPT (0.52) | KMT2AALDH1A1SMN1; SMN2MAPK1MEN1 | |
| SCHEMBL26337500 | 0.79 | ALDH1A1 (0.59) | KMT2AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2376910 | 0.78 | MAPK1 (0.46) | KMT2AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL10328260 | 0.78 | PIK3CA (0.60) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL11868217 | 0.78 | ALDH1A1 (0.49) | KMT2AKDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108467369-B | Biaryl amide compounds as kinase inhibitors | 诺华股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2020-07-14 | — | — | US | disclosed |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
| US-10245267-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2019-04-02 | — | — | US | disclosed |
| EP-3299367-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2018-03-28 | — | — | EP | disclosed |
| US-20170260207-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2017-09-14 | — | — | US | disclosed |
| EP-3204009-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9694016-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| WO-2009066084-A1 | 2 -MORPHOLINOPYRIMIDINES AND THEIR USE AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-05-28 | — | — | WO | disclosed |
| CN-101389622-A | Pyrimidine derivatives used as pi-3 kinase inhibitors | NOVARTIS AG (CH) | 2009-03-18 | — | — | CN | disclosed |
| EP-1984350-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | Novartis AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-3984411-A | HYPOCHOLESTEROLEMICS, HYPOGLYCEMICS OR ANTIDIABETICS | SOCIETE GENERALE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES "SOGERAS" (FR) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | GPR35, NPY1R, BDKRB1 | KMT2A 1861/4885KDM4E 1667/4885ALDH1A1 947/4885 |
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | HPSE, GAA, MAN2B1 | KMT2A 4081/4885KDM4E 3788/4885ALDH1A1 1376/4885 |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | KMT2A 756/4885KDM4E 1493/4885ALDH1A1 1592/4885 |
| US-20170260207-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | KMT2A 756/4885KDM4E 1493/4885ALDH1A1 1592/4885 |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | KMT2A 756/4885KDM4E 1493/4885ALDH1A1 1592/4885 |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | KMT2A 3700/4885KDM4E 3890/4885ALDH1A1 920/4885 |
| US-10245267-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | KMT2A 756/4885KDM4E 1493/4885ALDH1A1 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.